Abstract Details
|
Joao M. Lemos, MD
(Coimbra University Hospital Centre)
PRESENTER |
No disclosure on file |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Thomas A. Berger, MD (Dept. of Neurology, Medical University of Vienna) | Prof. Berger has received personal compensation in the range of $10,000-$49,999 for serving as a speaker at scientific meetings and participant of local and international advisory boards with various companies producing and markerting treatments for multiple sclerosis (Almirall, Biogen, Biologix, Bionorica, Celgene-BMS, Merck, Novartis, Roche, Sanofi-Genzyme, TG Therapeutics, UCB). |
| John K. Fink, MD | No disclosure on file |